Podcasts about Deletion

In this JCO Article Insights episode, Michael Hughes summarizes “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma" by Avet-Loiseau et al. published on June 09, 2025 along with an interview with author Dr Nikhil C. Munshi, MD. TRANSCRIPT Michael Hughes: Welcome to this episode of JCO Article Insights. This is Michael Hughes, JCO's editorial fellow. Today I am interviewing Dr. Nikhil Munshi on the “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma” by Avet-Loiseau et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. While some patients with multiple myeloma live for decades after treatment, others exhibit refractory or rapidly relapsing disease irrespective of treatment administered. We term this “high-risk myeloma.” Multiple risk stratification systems have been created, starting with the Durie-Salmon system in 1975 and evolving with the advent of novel therapeutics and novel treatment approaches. In 2015, the Revised International Staging System (R-ISS) was introduced, which incorporated novel clinical and cytogenetic markers and remained, until recently, a mainstay of risk stratification in newly diagnosed disease. Myeloma as a field has, just in the past few years, though, undergone explosive changes. In particular, we have seen groundbreaking advances not only in treatments - the introduction of anti-CD38 agents and the advent of cellular and bispecific therapies - but also in diagnostic technology and our understanding of the genetic lesions in myeloma. This has led to the proliferation of numerous trials employing different definitions of high-risk myeloma, a burgeoning problem for patients and providers alike, and has prompted attempts to consolidate definitions and terminology. Regarding cytogenetic lesions, at least, Kaiser et al's federated meta-analysis of 24 therapeutic trials, published here in the JCO in February of 2025 and recently podcasted in an interview with associate editor Dr. Suzanne Lentzsch, posited a new cytogenetic classification system to realize a shared platform upon which we might contextualize those trial results. This article we have here by Dr. Avet-Loiseau, Dr. Munshi, and colleagues, published online in early June of this year and hot off the presses, is the definitive joint statement from the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG). What is high-risk multiple myeloma for the modern era? The IMS and IMWG Genomics Workshop was held in July 2023 and was attended by international myeloma experts, collaborating to reach consensus based on large volumes of data presented and shared. The datasets included cohorts from the Intergroupe Francophone du Myélome (IFM); the HARMONY project, comprised of multiple European academic trials; the FORTE study, findings from which solidified KRd as a viable induction regimen; the Grupo Español de Mieloma Múltiple (GEM) and the PETHEMA Foundation; the German-Speaking Myeloma Multicenter Group (GMMG); the UK-based Myeloma XI, findings from which confirmed the concept of lenalidomide maintenance; Emory 1000, a large, real-world dataset from Emory University in Atlanta; the Multiple Myeloma Research Foundation Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) dataset; and some newly diagnosed myeloma cohorts from the Mayo Clinic. Data were not pooled for analyses and were assessed individually - that is to say, with clear a priori understanding of whence the data had been gathered and for what original purposes. Consensus on topics was developed based on the preponderance of data across studies and cohorts. In terms of results, substantial revisions were made to the genomic staging of high-risk multiple myeloma, and these can be sorted into three major categories: A) alterations to the tumor suppressor gene TP53; B) translocations involving chromosome 14: t(14;16) (c-MAF overexpression), t(14;20) (MAFB overexpression), and t(4;14) (NSD2 overexpression); and C) chromosome 1 abnormalities: deletions of 1p or additional copies of 1q. In terms of category A, TP53 alterations: Deletion of 17p is present in up to 10% of patients at diagnosis and is enriched in relapsed or refractory disease. This is well-documented as a high-risk feature, but the proportion of the myeloma cells with deletion 17p actually impacts prognosis. GEM and HARMONY data analyses confirmed the use of 20% clonal cell fraction as the optimal threshold value for high-risk disease. That is to say, there must be the deletion of 17p in at least 20% of the myeloma cells on a FISH-analysis of a CD138-enriched bone marrow sample to qualify as high-risk disease. TP53 mutations can also occur. Inactivating mutations appear to have deleterious effects similar to chromosomal losses, and the biallelic loss of TP53, however it occurs, portends particularly poor prognosis. This effect is seen across Myeloma XI, CoMMpass, and IFM cohorts. Biallelic loss is rare, it appears to occur in only about 5% of patients, but next-generation sequencing is nevertheless recommended in all myeloma patients. Category B, chromosome 14 translocations: Translocation t(14;16) occurs in about 2% to 3% of patients with newly diagnosed disease. In the available data, primarily real-world IFM data, t(14;16) almost always occurs with chromosome 1 abnormalities. Translocation t(4;14) occurs in about 10% to 12% of newly diagnosed disease, but only patients with specific NSD2 alterations are, in fact, at risk of worse prognosis, which clinically appears to be about one in every three of those patients. And so together, the CoMMpass and Myeloma XI data suggest that translocation t(4;14) only in combination with deletion 1p or gain or amplification of 1q correlates with worse prognosis. Translocation t(14;20) occurs in only 2% of newly diagnosed disease. Similar to translocation t(4;14), it doesn't appear to have an effect on prognosis, except if the translocation co-occurs with chromosome 1 lesions, in which case patients do fare worse. Overall, these three translocations - t(14;16), t(4;14), and t(14;20) - should be considered high-risk only if chromosome 1 aberrations are also present. In terms of those chromosome 1 aberrations, category C, first deletions of 1p: Occurring in about 13% to 15% of newly diagnosed disease, deletion 1p eliminates critical cell checkpoints and normal apoptotic signaling. In the IFM and CoMMpass dataset analyses, biallelic deletion of 1p and monoallelic deletion of 1p co-occurring with additional copies of 1q denote high-risk. In terms of the other aberration in chromosome 1 possible in myeloma, gain or amplification of 1q: This occurs in up to 35% to 37% of newly diagnosed disease. It upregulates CKS1B, which is a cyclin-dependent kinase, and ANP32E, a histone acetyltransferase inhibitor. GEM and IFM data suggest that gain or amplification of 1q - there was no clear survival detriment to amplification - is best considered as a high-risk feature only in combination with the other risk factors as above. Now, in terms of any other criteria for high-risk disease, there remains one other item, and that has to do with tumor burden. There has been a consensus shift, really, in both the IMS and IMWG to attempt to develop a definition of high-risk disease which is based on biologic features rather than empirically observed and potentially temporally dynamic features, such as lactate dehydrogenase. Beta-2 microglobulin remains an independent high-risk indicator, but care must be taken when measuring it, as renal dysfunction can artificially inflate peripheral titers. The consensus conclusion was that a beta-2 microglobulin of at least 5.5 without renal failure should be considered high-risk but should not preclude detailed genomic profiling. So, in conclusion, the novel 2025 IMS-IMWG risk stratification system for myeloma is binary. It's either high-risk disease or standard-risk disease. It's got four criteria. Number one, deletion 17p and/or a TP53 mutation. Clonal cell fraction cut-off, remember, is 20%. Or number two, an IGH translocation - t(4;14), t(14;16), t(14;20) - with 1q gain and/or deletion of 1p. Or a monoallelic deletion of 1p with 1q additional copies or a biallelic deletion of 1p. Or a beta-2 microglobulin of at least 5.5 only when the creatinine is normal. This is a field-defining work that draws on analyses from across the world to put forward a dominant definition of high-risk disease and introduces a new era of biologically informed risk assessment in myeloma. Now, how does this change our clinical approach? FISH must be performed on CD138-enriched samples and should be performed for all patients. Next-generation sequencing should also be performed on all patients. Trials will hopefully now begin to include this novel definition of high-risk multiple myeloma. It does remain to be seen how data from novel therapeutic trials, if stratified according to this novel definition, will be interpreted. Will we find that therapies being evaluated at present have differential effects on myelomas with different genetic lesions? Other unanswered questions also exist. How do we go about integrating this into academic and then community clinical practice? How do we devise public health interventions for low-resource settings? To discuss this piece further, we welcome the esteemed Dr. Nikhil Munshi to the podcast. Dr. Munshi is a world-renowned leader in multiple myeloma and the corresponding author on this paper. As Professor of Medicine at Harvard Medical School, Director of the Multiple Myeloma Effector Cell Therapy Unit, and Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute, he has presided over critical discoveries in the field.  Thank you for joining us, Dr. Munshi. Dr. Nikhil Munshi: Oh, it's my pleasure being here, Michael, to discuss this interesting and important publication. Michael Hughes: I had a few questions for you. So number one, this is a comprehensive, shall we say, monumental and wide-ranging definition for high-risk myeloma. How do you hope this will influence or impact the ways we discuss myeloma with patients in the exam room? And how do we make some of these components recommended, in particular next-generation sequencing, feasible in lower-resource settings? Dr. Nikhil Munshi: So those are two very important questions. Let's start with the first: How do we utilize this in our day-to-day patient care setting? So, as you know well, we have always tried to identify those patients who do not do so well with the current existing treatment. And for the last 30 years, what constitutes a myeloma of higher risk has continued to change with improvement in our treatment. The current definition basically centers around a quarter of the patients whose PFS is less than 2 to 3 years. And those would require some more involved therapeutic management. So that was a starting point of defining patients and the features. As we developed this consensus amongst ourselves - and it's titled as “International Myeloma Society, International Myeloma Working Group Consensus Recommendation” - this IMS-IMWG type of recommendation we have done for many years, improvising in various areas of myeloma care. Now, here, we looked at the data that was existing all across the globe, utilizing newer treatment and trying to identify that with these four-drug regimens, with transplant and some of the immunotherapy, which group of patients do not do as well. And this is where this current algorithm comes up. So before I answer your question straight, “How do we use it?” I might like to just suggest, “What are those features that we have identified?” There are four features which constitute high-risk disease in the newer definition. Those with deletion 17p with 20% clonality and/or TP53 mutation. Number two, patients with one of the translocations - t(4;14), t(14;16), or t(14;20) - co-occurring with 1q amplification or deletion 1p32. And that's a change. Previously, just the translocation was considered high-risk. Now we need a co-occurrence for it to be called high-risk. The third group is patients having biallelic deletion 1p32 or monoallelic deletion 1p32 along with 1q amplification. And finally, patients with high beta-2 microglobulin, more than or equal to 5.5 mg/dL, with normal creatinine less than 1.2 mg/dL. And the question, “How do we use this?” There are multiple areas where we incorporate high-risk features in our treatment algorithm. One of the first areas is where we would consider the induction regimen. If a patient has a high-risk disease, we would definitely consider a four-drug regimen rather than a three-drug regimen, although we are beginning to incorporate four-drug for all groups. That's one important thing. Number two, those are the patients where we do consider consolidation with transplant or maybe in the new world, considering some of the immunotherapeutic consolidation more early or more aggressively. Number three, these are the patients who get a little bit more maintenance therapy. So normally, lenalidomide might end up being our standard maintenance regimen. In patients who have high-risk disease, we incorporate either addition of daratumumab or the anti-CD38 targeting antibody and/or addition of proteasome inhibitor, either bortezomib or carfilzomib. So you would have multi-drug maintenance therapy in these patients. And in high-risk patients, we follow them with maintenance longer periods of time. One very critically important point to keep in mind is that to get the better outcome in high-risk disease, we must try to get them into MRD negativity because there is clear data that patients who do achieve MRD negativity, despite having high-risk disease, have a much superior outcome. They become near to standard-risk disease. And so, in high-risk patients, I would try to do whatever various options I have to try and get them into MRD-negative status. And when these patients relapse, we do not wait for the classic progression criteria to be met before we intervene. We would propose and suggest that we intervene earlier before the disease really blasts off. And so there are a number of areas in our setting where this high-risk definition will help us intervene appropriately and also with appropriate aggressiveness to achieve better outcome, to make this similar to standard-risk disease. Michael Hughes: Thank you, Dr. Munshi. And thoughts on how to really integrate this not only into academic centers but also lower-resource settings? Dr. Nikhil Munshi: So that's a very important question, Michael. And when we were developing this consensus, we were very cognizant of that fact. So wherever available, I think we are recommending that over a period of next 2, 3, 5 years, we should begin to switch over to sequencing-based methods because two components of this definition, one is TP53 mutation, which we cannot do without sequencing, and also reliably detecting deletion 1p requires sequencing-based method. So in the low-resource countries - and there are many in this world, and also even in our own country, patients may not be able to afford it - the older method with FISH or similar such technology, which is more affordable, is also acceptable for current time. They may miss a very small number of patients, maybe 2% to 3%, where these finer changes are not picked up, but a majority of this would be captured by them. So the current practice might still be applicable with some limitation in those patient populations, and that's what we would recommend. What is happening, fortunately, is that actually sequencing-based method is becoming cheaper. And in many centers, it is cheaper to do the sequencing rather than to do the FISH analysis. And so my hope is that even in low-resource centers, sequencing might be more economical in the end. It's, I think, the access to technology, which is a little bit limited currently, but it's hopefully becoming available soon. Michael Hughes: Thank you, Dr. Munshi. And staying for a minute and looking at the multiple myeloma subsets which might be missed by this really still very broad-ranging high-risk definition, at least by prior risk stratification systems, right, there is this group of patients who have standard-risk cytogenetics by R-ISS or R2-ISS, but they have primary refractory disease or they relapse early. We call these, as you are well aware, functionally high-risk disease. What proportion of previously FHR, functionally high-risk, myeloma patients do you expect to be captured by this novel definition? Dr. Nikhil Munshi: So I think the newer definition - and we can look at it both ways, but the newer definition should capture most of the functionally high-risk definition. To put it differently, Michael, there are patients who we know are, as you mentioned, functionally high-risk. Those are the patients who might have plasma cell leukemia, those who might have extramedullary disease, those who might not respond to our four-drug induction. If you don't respond to the four-drug induction, almost by definition, they are high-risk. However, a majority of them have one of the abnormalities that we are describing here. There would be a very small proportion which may not have. And if they do not have, we know one of the important components of this definition here is also that the genome, we know, keeps on evolving. So there may be a very small clone with the high-risk feature which was not obvious in the beginning. Following treatments or following relapse, that clone predominates, and now the patient's disease becomes high-risk.  So the definition would incorporate or would capture these functional high-risk patients, but as you said, in countries where resources are not available, using this functional high-risk would also be helpful and advantageous. Sometimes LDH ends up being a high-risk. In our studies, LDH has not come out to be high-risk anymore because the features we are describing captures most of those patients, but those alternatives, older, can still be considered if other newer techniques are not available. Michael Hughes: Got you. And in terms of these older definitions, yes, that incorporate tumor burden, these empirical observations about how myeloma presents, do you foresee any additional tumor burden indicators being added to future definitions of high-risk disease? Or do you instead see this particular definition as a major waypoint on the journey towards a fully biologically grounded definition of high-risk disease? Dr. Nikhil Munshi: I think your second part is what is going to happen. I think the tumor burden-related definition is being now replaced by the biological or genomic-based definition. And I think at some point, it will be quite fully replaced. One component not here, and it is because one thing, we don't have enough data; number two, we don't know how it will pan out, is also the influence of the microenvironment on the risk definition. For example, the immune system, the immune function, etc. But not enough data exists to suggest how it would change the current definition. So in future, would a definition be totally genomic or it could be more integrative? And my personal guess is that it would be more integrative and that some immune features might come into the picture, especially now that we are using immune-based therapy as a very important component of treatment - CAR T-cells, bispecific, and antibody-based treatments. What role the immune system plays in either supporting tumor or what role suppression of the anti-tumor immunity plays? They all will be important how patient outcomes end up being, and which in turn could translate into how patient's risk stratification might happen. So I think the older tumor burden-related definitions probably will become things of the past. What we have currently proposed and consensus developed is the new path forward, and over time, some microenvironmental influences, if defined and found to be important, may get some more incorporation if it compares favorably with the genomic features. Michael Hughes: Thank you, Dr. Munshi for that enlightening response.  To conclude the podcast, I'd like to look to the future and to the immediate future, what are the next steps for high-risk disease definition between now and discussing an integrated genomic-microenvironment-based definition? Will we see attempts to refine? Will we see a multi-level system, things like this? Dr. Nikhil Munshi: Yeah, so I think the current definition will be here to stay for the next 10 years or so. I think this has been developed using a large amount of data, so we do believe that this will remain fine. It has been validated now within the last six months by a few of the other studies. So there won't be a quick change. But we will try to, all of us will try to innovate. And as you very rightly bring up, the areas of research would include looking at the expression or transcriptomic component. Does that matter? And we do believe a small number of patients will have transcriptomic changes, not looked at the DNA changes, and may play a role. There are newer components, so long non-coding RNA, for example, is going to be an important component to look at, how it impacts the disease outcome, etc. There are also some of the proteomic-related changes which may become important in our studies. And then as we discussed, microenvironment and immunological changes. So these are the future areas of ongoing research where we all should collect data, and then in the next 5 to 10 years, we'll have another group meeting to see has anything changed or any of the features have become more important.  Most of the time, some of the older features are lost because they are not as critically high-risk, and the newer features come in. And so the historical background for just one second, there was a time when chromosome 13 was considered a high-risk disease. We now don't even mention it because it's not high-risk. The newer treatments have improved the outcome. t(4;14) used to be a high-risk disease. Now by itself today, in this definition by itself is not; it needs to be with something else. And so I think this is a great sign of progress. As we improve the treatment and outcomes, some of the features will become less important, new features will come up, and we'll need to keep on evolving with time and with technology and make it better for patients. Michael Hughes: Thank you so much, Dr. Munshi, for your wisdom, for your sagacity, for your historical perspective as well.  Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries. And be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Get the stories from today's show in THE STACK: https://justinbarclay.comKirk Elliott PHD - FREE consultation on wealth conservation - http://GoldWithJustin.comJoin Justin in the MAHA revolution - http://HealthWithJustin.comTry Cue Streaming for just $2 / day and help support the good guys https://justinbarclay.com/cueUp to 80% OFF! Use promo code JUSTIN http://MyPillow.com/JustinPatriots are making the Switch! What if we could start voting with our dollars too? http://SwitchWithJustin.com

  In this episode of #Trending, hosted by Dr. Hamma sitting in for Jim Love, we explore the longest ChatGPT outage ever, which lasted over 12 hours and exposed our growing dependency on AI. We also discuss Wikipedia's paused AI summary experiment due to negative feedback from editors, and the growing privacy concerns as nearly 15% of 23andMe customers request data deletion amidst the company's bankruptcy sale. Finally, we cover Google's new Gemini feature for Google Sheets, which promises to simplify the creation and editing of spreadsheet charts, addressing a common productivity pain point. 00:00 Introduction and Headlines 00:34 ChatGPT Outage: A Wake-Up Call 03:32 Wikipedia's AI Summary Experiment Halted 06:15 23andMe Bankruptcy and Data Privacy Concerns 09:16 Google's Gemini Revolutionizes Spreadsheet Charts 11:46 Conclusion and Sign-Off

Daily Scoop listeners and readers of FedScoop will recall the shocking news earlier this year when 18F, a decade-old digital services consultancy in the General Services Administration, was shuttered by the Trump administration's Department of Government Efficiency. Members of the team have banded together since their termination to keep an active presence online through 18F.org in the wake of their dismantling. But the group isn't going out without a fight. Several senior members of 18F in late May filed a class action appeal to the Merit System Protection Board claiming that GSA lacked a “valid reason” for firing them and targeted them as an act of “retaliation” for their political beliefs. In the appeal, they call for a hearing and to have their removal reversed. Lindsay Young is the former executive director of 18F and one of the name appellants representing the class in the appeal. She joins the podcast for a conversation about how the “deletion” of 18F went down, what she and her team have been doing since, and what they hope to accomplish with the appeal. U.S. officials violated federal privacy law and flouted cybersecurity protocol in sharing Office of Personnel Management records with DOGE affiliates, a federal district court judge in New York ruled Monday, granting a request for a preliminary injunction against the administration. In a 99-page order, Judge Denise Cote of the U.S. District Court for the Southern District of New York concluded that federal worker and union plaintiffs had shown that the government defendants in the challenge shared OPM records with “individuals who had no legal right of access to those records” in violation of the Privacy Act of 1974 and cybersecurity standards. “This was a breach of law and of trust,” Cote said in the order. “Tens of millions of Americans depend on the Government to safeguard records that reveal their most private and sensitive affairs.” The ruling is the latest in a challenge to DOGE's data access at OPM brought by a coalition of federal unions and current and former government employees or contractors. A new executive order from President Donald Trump aims to boost drone manufacturing in the United States, an effort the administration hopes will spur productivity and technological development and secure the country's industrial base. Meanwhile, a second executive order aims to combat the risk that, as drone usage proliferates, the technology could also be used to threaten public safety and endanger critical infrastructure. The “Unleashing American Drone Dominance” and “Restoring American Airspace Sovereignty” executive orders, both signed last Friday, come amid growing concerns about the operation of the National Airspace System, the airspace the Federal Aviation Administration monitors for commercial flights, space launches, and other aerial activity. Drones, sometimes called unmanned aerial systems, are also used to smuggle drugs and assist in criminal activity. Unauthorized UASs have increasingly shown up near some nuclear facilities, military bases, and commercial airports, raising concerns, too. The new executive order on airspace sovereignty aims to combat the problem, broadly charging federal agencies to detect drone activity, which will require the use of tracking and identification technology. The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast  on Apple Podcasts, Soundcloud, Spotify and YouTube.

Lt. Col. Tony Schaffer, Congressman Kurt Weldon, and Maj. Erik Kleinsmith exposes how the U.S. government blocked, buried, and deleted a groundbreaking intel program—Able Danger—that flagged 9/11 targets before the attack. From erased data to Senate censorship, this is the real story.

Life is good once you master the art of Deletion. Every day my laptop is full of emails asking for money to do worthwhile, even noble, things, which, if I donated to them, I'd soon be living in a cardboard box in a vacant lot, and so I click on “Unsubscribe” and they go away for a while. Instead, I google “What is the prospect of international peace and understanding?” and find that the U.N. thinks it's inevitable and dalailama.com says it's based on compassion and foreignpolicy.com thinks the prospects are not good. We didn't used to have Google, my kiddoes, we used to sit and worry about these things and now at last clear answers are available. Contradictory, but still. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit garrisonkeillor.substack.com/subscribe

Wrong Sender and DNA Data Deletion! full 2125 Tue, 25 Mar 2025 15:40:47 +0000 QgcaZmZq0Bf3CKGqUCow4kKWGmhvLHwP news Adam and Jordana news Wrong Sender and DNA Data Deletion! Coming at the news of the day from very different perspectives, Adam & Jordana have candid, fun, and sometimes serious conversations about current events along with all the other daily things that impact Minnesotans. Weekday mornings 9a-noon on NewsTalk 830 WCCO. 2024 © 2022 Audacy, Inc. News False https://player.amperwavepodcasting.com?feed-link=https%3A

We all have the same amount of time in a day. So, why are some managers better people leaders than others?In this episode of the Shedding the Corporate Bitch Podcast, host Bernadette Boas delves deep into a common challenge faced by corporate and entrepreneurial leaders alike: effectively managing time to prioritize your people. Bernadette shares her insights and strategies for putting your team first, highlighting the pivotal role employees play as the number one asset in any organization.Key Challenges Addressed:The conflict between existing commitments and dedicating time to employee engagement.Leaders' struggle to make their people a top priority due to overloaded calendars.Difficulty in setting boundaries and learning to say "no" to less critical tasks.Key Talking Points:The Priority of People: Bernadette challenges leaders to question if they're truly making their people their number one asset. Through global client experiences, she reveals the disconnect many employees feel despite leadership's intentions.Time Management and Prioritization: The episode dives into practical methods for time management, urging leaders to re-evaluate their schedules. Bernadette emphasizes the importance of creating ‘white space' on calendars to engage with team members.Setting SMARTY Goals: Bernadette introduces her unique approach to goal-setting, integrating the idea of personal accountability (the ‘Y' for ‘You') and aligning leadership goals with these metrics.The Four Ds Strategy: Delegation, Delay, Deletion, and Doing – learn how harnessing these can streamline tasks and safeguard time for people-focused activities.Time Blocking as a Tool: Discover how strategic time-blocking has transformed productivity and well-being for leaders and can create a balance between professional obligations and personal life.For leaders eager to elevate their approach, this episode is a valuable resource for understanding and overcoming time management barriers. Tune in now to uncover ways to truly put your people first!Subscribe and Review: Don't miss our weekly episodes! Subscribe on Apple Podcasts, Spotify, or wherever you enjoy your podcasts. Be sure to check out our visual content on the Shedding the Bitch YouTube channel.Call To Action: If this episode resonates with you, consider booking a discovery call with Bernadette Boas to discuss transforming your leadership and team engagement strategies.Keep shedding, keep growing, and keep thriving as a leader.Support the show

We all have the same amount of time in a day. So, why are some managers better people leaders than others?In this episode of the Shedding the Corporate Bitch Podcast, host Bernadette Boas delves deep into a common challenge faced by corporate and entrepreneurial leaders alike: effectively managing time to prioritize your people. Bernadette shares her insights and strategies for putting your team first, highlighting the pivotal role employees play as the number one asset in any organization.Key Challenges Addressed:The conflict between existing commitments and dedicating time to employee engagement.Leaders' struggle to make their people a top priority due to overloaded calendars.Difficulty in setting boundaries and learning to say "no" to less critical tasks.Key Talking Points:The Priority of People: Bernadette challenges leaders to question if they're truly making their people their number one asset. Through global client experiences, she reveals the disconnect many employees feel despite leadership's intentions.Time Management and Prioritization: The episode dives into practical methods for time management, urging leaders to re-evaluate their schedules. Bernadette emphasizes the importance of creating ‘white space' on calendars to engage with team members.Setting SMARTY Goals: Bernadette introduces her unique approach to goal-setting, integrating the idea of personal accountability (the ‘Y' for ‘You') and aligning leadership goals with these metrics.The Four Ds Strategy: Delegation, Delay, Deletion, and Doing – learn how harnessing these can streamline tasks and safeguard time for people-focused activities.Time Blocking as a Tool: Discover how strategic time-blocking has transformed productivity and well-being for leaders and can create a balance between professional obligations and personal life.For leaders eager to elevate their approach, this episode is a valuable resource for understanding and overcoming time management barriers. Tune in now to uncover ways to truly put your people first!Subscribe and Review: Don't miss our weekly episodes! Subscribe on Apple Podcasts, Spotify, or wherever you enjoy your podcasts. Be sure to check out our visual content on the Shedding the Bitch YouTube channel.Call To Action: If this episode resonates with you, consider booking a discovery call with Bernadette Boas to discuss transforming your leadership and team engagement strategies.Keep shedding, keep growing, and keep thriving as a leader.Support the show

Covino & Rich laugh about an Ash Wednesday flex & Rich tells a great Pope-Mobile story! They talk P-word, an arrowhead chip & a chicken tender Italy. Cove makes Dana's case to uplift boxing! 'MID WEEK MAJOR' kicks off with LeBron's 50,000 points. Plus, Maxx's money, & KD/Angel Reese a potential power couple?See omnystudio.com/listener for privacy information.

Dr Thomas Cassini explains how the Undiagnosed Diseases Network group used advanced sequencing techniques to clarify the genotype in a child with an unusual phenotype for mitochondrial trifunctional protein deficiency. Mitochondrial trifunctional protein deficiency caused by a deep intronic deletion leading to aberrant splicing Thomas Cassini, et al https://doi.org/10.1002/jmd2.12459

Trump's strategy shift on Taiwan's status quo on statehood reflects a broader shift in American strategy, particularly under figures like Marco Rubio and Elbridge Colby, who have emphasized the growing threat from China rather than Russia. In Ep 1608 of #CutTheClutter, ThePrint Editor-in-chief Shekhar Gupta looks at the implications of Trump's course correction on Taiwan, an incensed China's strategic warfare to contain Taiwan, and why India should take note. Research by Varnika Dhawan----more----Read Lowly Institute's report here: https://interactives.lowyinstitute.org/features/one-china-contest-to-define-taiwan/----more----Read The Economist's article here: https://www.economist.com/international/2025/02/09/chinas-stunning-new-campaign-to-turn-the-world-against-taiwan

Email me for a free trial of my Fast-Track to Fluency course!https://azrenthelanguagenerd.com/contact

Send us a textRu Kovvuri explains about her battle to get a diagnosis and support for her daughter who had multiple medical problems and learning difficulties as a result of a deletion of the HNF1B gene. Rhian Clissold discusses her research to improve the diagnosis of the HNF1B syndrome and recognise the associated learning difficulties seen with loss (deletion)  but not the spelling mistakes (mutations) in the HNF1B gene.

A reporters' podcast about what made news and what shouldn't have.NL TeamThis week, host Shivnarayan Rajpurohit is joined by Sumedha Mittal.Sumedha's series for Newslaundry, Broken Ballots, tracked curious deletions and additions of voters to the electoral rolls. Based on data and fieldwork, she found an odd pattern, which she says places a question mark on the Election Commission. She also cautions that this could be “used as exploitation”, regardless of whoever is in power. Tune in.Timecodes00:00:00 - Introduction00:02:18 - The Broken Ballots series00:50:20 - RecommendationsRecommendationsSumedhaA day with AAP volunteers who reflect the party's convoluted social-justice politicsShivnarayanVajpayee: The Ascent of the Hindu Right, 1924–1977Produced and edited by Saif Ali Ekram, recorded by Anil Kumar. Hosted on Acast. See acast.com/privacy for more information.

Bizarre end for Green Beret Bronze Star recipient who unalived himself in a Tesla Cybertruck at Trump hotel. Honk if you understand this obscure bumper sticker. Boundaries to set in the new year. Freedom Family Friday! @Steffip4Liberty  

Public records experts say the allegation that Goldberg ordered a state employee to delete texts — and potentially destroyed her own — raises a red flag.

Medboard: https://www.medboard.com/ EUROPE TEAM NB - Code of Conduct for NB -  Version 5: https://www.team-nb.org/wp-content/uploads/2024/09/PressRelease-CoC-20240916.pdf TEAM NB - IVDR Transition - Transition to the implementation of Class D oversight by EURLs: https://www.team-nb.org/wp-content/uploads/2024/10/PressRelease-ClassD-20241001.pdf Title: MDCG 2021-4 Rev 1 update-  Deletion, revision, addition of questions: https://health.ec.europa.eu/document/download/9f23fca0-f407-4e45-a464-2d71b575d1fe_en?filename=mdcg_2021-4_en.pdf  Swissmedic - Deadline for Swissdamed - November 13th, 2024: https://www.swissmedic.ch/swissmedic/en/home/medical-devices/overview-medical-devices/archive/swissdamed/swissdamed-frist-13-11-24.html  Swiss review of old legislation devices -  Check that all are up-to-date: https://www.swissmedic.ch/swissmedic/en/home/medical-devices/overview-medical-devices/aufforderung-ueberpruefung-altrechtlicher-produkte.html  UK on their new Regulation -  Restart ongoing: https://medregs.blog.gov.uk/2024/09/25/an-update-on-our-plans-for-med-tech-regulatory-change/ EVENTS  TEAM-PRRC - Subtitle: October 17-18. 2024: https://medtechconf.com/event/team-prrc-third-annual-summit/  Afrisummit - Subtitle: November 3-6, 2024: https://medtechconf.com/event/afrisummit/  MEDICA - Subtitle: November 11-14, 2024 : https://medtechconf.com/event/medica-2024/ NB ISS IVDR Notified Body -  ISTITUTO SUPERIORE DI SANITA': https://webgate.ec.europa.eu/single-market-compliance-space/notified-bodies/notifications/1010586?organizationVersion=3 ROW Middle East  Saudi Arabia: Labelling Guidance - What should contain a Medical Device Label in Saudi Arabia: https://www.sfda.gov.sa/sites/default/files/2024-10/MDS-014En.pdf Northern America Title: USA webinar on Registation & Listing Requirements -  In-Vitro Diagnostics and Laboratory Developed Tests: https://www.fda.gov/medical-devices/cdrhnew-news-and-updates/webinar-registration-listing-requirements-in-vitro-diagnostic-products-ivds-including-laboratory USA Guidance on Dental products -  Air Powered handpiece, Dental Cements, Dental Ceramics, Impressions: Air powered: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/air-powered-dental-handpieces-and-air-motors-performance-criteria-safety-and-performance-based Dental Cements: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-cements-performance-criteria-safety-and-performance-based-pathway Dental Ceramics: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-ceramics-performance-criteria-safety-and-performance-based-pathway Dental Impressions: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-impression-materials-performance-criteria-safety-and-performance-based-pathway  Canada policy on Drug/device combinations - Who is who?: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/policies/policy-drug-medical-device-combination-products-decisions.html South America: Brazil bans - Thermometers and Sphygmomanometers with a  Mercury column: https://antigo.anvisa.gov.br/documents/10181/6873945/RDC_922_2024_.pdf/1e09cbf1-53db-4609-bea7-34afb7ce633c PODCAST Podcast Nostalgia -  Last podcast to listen to- Episode 302 - How to do PMCF literature Search for Medical Devices with Cesare Magri 4BetterDevices: https://podcast.easymedicaldevice.com/302-2/ Episode 303 - UK vs EU vs US - How to switch to another region easily? With Claire Dyson DQS : https://podcast.easymedicaldevice.com/303-2/ Episode 304 - How to select the best plastic for your Medical Device? Lucas Pianegonda Gradical: https://podcast.easymedicaldevice.com/305-2/   Social Media to follow Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi Twitter: https://twitter.com/elazzouzim Pinterest: https://www.pinterest.com/easymedicaldevice Instagram: https://www.instagram.com/easymedicaldevice

Head of IT at the Electoral Commission, Dr. Yaw Ofori AGYEI, underlying IT management process on voters register at IPAC meeting denied allegation from NDC of deletion and transfer of votes from different polling stations

George Soros has been leaning on the Democrat-controlled Federal Communications Commission for months in hopes of fast-tracking his group's acquisition of over 200 radio stations in over 40 markets, including those running conservative programming. This appears to be another left-wing abuse of power where the FCC is now willingly consigning and supporting Soros' latest power play for narrative dominance. It is a grave decision amid a broader “weaponization of government power against free speech.” Meanwhile, Alex Jones's empire is now being liquidated because of something he said; the whole process is a show trial. It's an excessive example of how speech can be curtailed and how thought crime is alive and well. Tonight on Ground Zero (7-10 pm, pacific time), Clyde Lewis talks with media consultant, Mark Masters about THE SENTINEL CLASS -WEAPONS OF MASS DELETION. Listen Live: https://groundzero.radio Archived Shows: https://aftermath.media

Dr Richard Kirschner, Dr Adriane Baylis, and Chaitali Amin visit the studio as we explore the 22q11.2 Deletion Syndrome. We discuss this genetic condition's cause, features, diagnosis, management, and long-term outlook. We hope you can join us!

Join us for an enlightening episode as we delve into the unique insights of Ashlyn Crockett, a passionate advocate and parent navigating the intersections of 18q Deletion Syndrome and cleft lip and palate diagnoses. Based on her personal journey and expertise, Ashlyn shares invaluable experiences and knowledge about these rare conditions, shedding light on their impact on individuals and families alike. Throughout the discussion, Ashlyn provides deep insights into the complexities of managing 18q Deletion Syndrome alongside cleft lip and palate diagnoses. Her perspective as a parent and advocate offers listeners practical advice, resilience strategies, and heartfelt encouragement for anyone facing similar challenges. Whether you're seeking to understand these conditions better or looking for support in a similar journey, Ashlyn Crockett's expertise and compassionate voice will leave you informed, inspired, and empowered. Tune in to gain a deeper understanding of 18q Deletion Syndrome and cleft lip and palate diagnoses, and discover pathways to navigate them with grace and strength. Follow Ashlyn @ashlyn.blakeee on Instagram Want to share your story? Email us at ourforeversmiles@gmail.com. Want to be a show sponsor? Email us at ourforeversmiles@gmail.com Follow us @ourforeversmiles on social platforms We know you will have questions! Join our FB Community to discuss the weekly episode and speak directly to our guests. https://www.facebook.com/groups/1081522212884073/ _______________________________________________________________________________ This podcast is completely free for you, but if you'd ever consider supporting the show, we truly appreciate it. One way you can do that is by using our affiliate links. These are links to products we've mentioned on the show, and if you make a purchase through one of them, we might earn a small commission at no extra cost to you. It's a great way to show your love for the podcast and help us keep creating content that educates, empowers, and strengthens the cleft lip and palate community! First Bottle to Purchase After Palate Repair - Post Palate Repair Straw Trainer Juselle's Cleft Palate Bottle - Pigeon Bottle Specialty Feeder Sippy Cup for Pre Palate Repair Prep - Munchkin 360 Weigh your Baby at Home - Weighted Feeds Scale Squeezable Straw Training Bottle - Honey Bear Straw Cup Free Flow Cup for Pre palate Repair Prep - Reflo Smart Cup Pacifiers that have Worked for Cleft Lip and Palate Babies - Itzy Ritzy Pacifiers that have Worked for Cleft Lip and Palate Babies - MAM Pacifiers that have Worked for Cleft Lip and Palate Babies - Itzy Ritzy Scar Cream Recommended by Alexis Garcia, Cleft Lip Mom - bioCorneum - Pricey**

Microsoft Planner for the Web catches up with the Planner app in Teams. But some features will be late and some, lost. OneDrive warns about deletion of shared files. Teams now lets admins block a user from chatting with anyone in your organisation.   Daniel and Darrell now share their 365 Message Center message sorting with a live audience. Join the live stream and the chat. Contribute to the show and tell us which messages are important to you and why.

Send us a textWhat would you do if you suddenly discovered that multiple members of your family were living with an intricate genetic condition? Join us for a heartfelt conversation with Regina Lawrence as she opens up about her family's journey with DiGeorge syndrome (a.k.a. 22q11.2 deletion syndrome). From the moment they learned about Aubrey's diagnosis in utero, to the immediate surgeries that followed her birth, Regina shares the raw, emotional experiences of navigating multiple complex medical needs. Dive into the Lawrence family's world, where resilience is not just a necessity but a way of life.Listen as Regina recounts the unexpected revelation of her husband's diagnosis at age 35 and the impact it had on their family dynamics. Discover how the Lawrences juggle specialized medical care, feeding challenges, and the critical role of American Sign Language and communication tablets in Aubrey's day-to-day life. Learn about Tina, Aubrey's sister, and the family's experiences at Boston Children's Hospital. Regina's advocacy work within the CHD community also offers a passionate perspective on why genetic testing is paramount. This episode promises to leave you with a profound understanding of DiGeorge syndrome and the unbreakable spirit of a family united in their fight.Link to The CHC Podcast: Congenital Heart Conversations: https://tinyurl.com/CHCPodcastAppleThanks to our newest HUG Patron, Ayrton Beatty and long-standing Patrons: Laura Redfern, Pam Davis, Michael Liben, Nancy Jensen, Alicia Lynch, Deena Barber, Carlee McGuire, Carter & Faye Mayberry, and Frank Jaworski. We appreciate you!Support the showAnna's Buzzsprout Affiliate LinkBaby Blue Sound CollectiveSocial Media Pages:Apple PodcastsFacebookInstagramMeWeTwitterYouTubeWebsite

Join Rachel and Dr. John Williams on CPW's late announcement to relocate a wolf pack to an undisclosed location, the First Gentleman's apparent tiff with ranchers on The Facebook, and the single best argument I've heard made in the wolf debate. This podcast is made possible by Adam Rose's Iliff Custom Cabinetry, Premier Farm Credit, and Your Choice Meats. The ProAg Podcast was created and produced by me, Rachel Gabel.

On this episode Lara and Vyanka talk to Dr Kathleen Sullivan from the Children's Hospital of Philadelphia all about DiGeorge Syndrome and 22q11 Deletion Syndrome. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

Using a NLP concept of self-talk. Deletion, Distortion & generalization. And how to use these to Brainwash the brain to live in the NOW.

Good morning and welcome to the ride!  The Chief Love Officer has to warn a woman about a man that is locked up.  What reasons does your wife need to delete you?  Yachts, sex and mates is in Would You Rather.  Shirley has a question tied directly to sleep just for the crew.  What's up with the no sex and Olympians in Paris?  We also find out how to tell which member of the crew is lying.  Today in Closing Remarks, Steve points out the importance of fighting for your dreams.Support the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

What reasons does your wife need in order to kill you?See omnystudio.com/listener for privacy information.

Love won't really happen when you least expect it if you don't get out from behind your screen and meet people in real life

This Day in Legal History: Patent Cooperation Treaty SignedOn June 19, 1970, the Patent Cooperation Treaty (PCT) was signed, marking a significant milestone in international intellectual property law. The PCT established a unified procedure for filing patent applications to protect inventions in multiple countries. Prior to the PCT, inventors needed to file separate patent applications in each country where they sought protection, a costly and time-consuming process.The PCT streamlined this by allowing inventors to file a single international application, which could then be pursued in each contracting state. Managed by the World Intellectual Property Organization (WIPO), the treaty aimed to simplify and reduce the cost of obtaining multinational patent protection.The system introduced by the PCT has two main phases: the international phase and the national phase. During the international phase, the application is reviewed for formal requirements and subjected to an international search and preliminary examination. In the national phase, the application enters the national jurisdictions of the chosen countries for further examination according to local laws.The PCT has been crucial in promoting innovation and technological advancement by providing a more efficient path for securing patent rights internationally. Today, over 150 countries are members of the PCT, reflecting its global acceptance and importance in the realm of intellectual property.Senate Democrats canceled a procedural vote to advance President Biden's nominee, Mustafa Kasubhai, for a federal district court judge in Oregon. Majority Leader Chuck Schumer cited attendance issues as the reason for postponing the cloture vote, which will be rescheduled soon. With a narrow 51-49 majority, Democrats face challenges in confirming controversial nominees. Kasubhai, currently a magistrate judge, would be among the few Muslim Americans to serve as a life-tenured federal judge.His nomination has faced strong GOP opposition, with Republicans questioning his views on diversity, equity, inclusion, and the use of preferred pronouns in his courtroom. They have also scrutinized his past writings, some dating back to his time as a law student, and accused him of holding radical views, including Marxism. The absence of Sen. Robert Menendez, due to his bribery trial, and potential opposition from Sen. Joe Manchin, who demands bipartisan support for nominees, complicate Kasubhai's confirmation prospects.Senate Democrats Pull Vote on Trial Court Nominee Kasubhai (1)A banking industry challenge to the Consumer Financial Protection Bureau's (CFPB) rule capping credit card late fees at $8 will remain in Texas after the Fifth Circuit Court of Appeals blocked a transfer to Washington, D.C. The case, filed by the U.S. Chamber of Commerce and several banking associations, was initially moved by Judge Mark Pittman, who argued it was better suited for the District of Columbia due to the lack of affected banks in Texas. However, the appellate court halted the transfer, noting the nationwide impact of the CFPB's rule.Judge Don Willett emphasized that the case's broad implications extended beyond Texas, making it inappropriate to consider it a localized issue. The CFPB and the plaintiffs will continue to argue over the venue. This decision comes amidst broader concerns about venue shopping, with industry groups favoring Texas courts perceived as more sympathetic to their challenges against federal regulations. The CFPB's credit card late fee rule, introduced on March 5, aims to reduce so-called junk fees and could significantly impact banks' revenue, potentially costing them $10 billion annually. The banking industry quickly filed a lawsuit to block the rule, reflecting its substantial financial stakes. The Fifth Circuit's ruling highlights the ongoing tension between regulatory efforts and industry pushback.Credit Card Late Fee Suit Kept in Texas Again by 5th Cir. (1)A San Francisco federal judge has sanctioned Apple Inc. in a privacy class action lawsuit by barring certain defenses due to the deletion of audio recordings from its Siri voice assistant. Magistrate Judge Sallie Kim of the US District Court for the Northern District of California ruled that Apple failed to halt its data retention policy after the lawsuit was filed, resulting in the destruction of electronically stored information (ESI) central to the case.Apple had argued that the deleted data was irrelevant, but the court disagreed. As a result, Apple is prohibited from making several defenses, including claims that plaintiffs lack standing due to insufficient evidence of false Siri triggers, arguments against class-wide damages based on the number of false recordings, and defenses regarding Apple's intent based on repeated false recordings.The lawsuit, initiated in 2019, accuses Apple of violating wiretap laws by intercepting and misusing private conversations through Siri without users' intentional activation. Plaintiffs alleged that Apple continued deleting relevant recordings years after the litigation began, thus deliberately interfering with the case.Judge Kim indicated that a jury must decide whether Apple's deletion of information was intentional, which could lead to further sanctions. The plaintiffs are represented by Lexington Law Group LLP, Lowey Dannenberg PC, and Scott & Scott LLP, while Apple is represented by DLA Piper LLP and Morrison & Foerster LLP. The case is Lopez v. Apple, Inc.Apple Restricted on Siri Trial Defenses for Deleting RecordingsThe U.S. Federal Trade Commission (FTC) has referred a complaint against TikTok and its parent company, ByteDance, to the Justice Department over potential violations of children's privacy laws. This action stems from an investigation that found reasons to believe TikTok might be violating the law, prompting the FTC to seek legal proceedings in the public interest. The FTC typically keeps such referrals confidential but made an exception in this case.The complaint follows earlier reports from 2020 that the FTC and the Justice Department were investigating TikTok for allegedly failing to comply with a 2019 agreement to protect children's privacy. TikTok expressed disappointment over the FTC's decision to pursue litigation instead of seeking a settlement, claiming that many of the allegations are outdated or inaccurate.This investigation is separate from ongoing Congressional concerns about the potential misuse of data from TikTok's 170 million U.S. users by the Chinese government, an allegation TikTok denies. Additionally, TikTok is preparing to file a legal brief against a law requiring ByteDance to divest TikTok's U.S. assets by January 19 or face a ban.The FTC's actions highlight the heightened scrutiny TikTok faces regarding privacy and national security issues in the U.S.Child privacy complaint against TikTok referred to US Justice Dept | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Emma Ansah reports on Ontario's new DNA technology that helped Niagara Police solve and identify the suspect responsible for the deletion of a Black woman 25 years ago --- Send in a voice message: https://podcasters.spotify.com/pod/show/africandiasporanews/message Support this podcast: https://podcasters.spotify.com/pod/show/africandiasporanews/support

In this episode of the Epigenetics Podcast, we talked with Nadav Ahituv from University of California, San Francisco about his work on mutations of gene regulatory elements in human disease. Using massively parallel experiments, his lab revolutionized functional genomics by studying the impact of transcription factor binding sites on gene expression. His groundbreaking technology deciphered the regulatory language of gene expression by exploring transcription factor combinations, spacing, and orientation. By delving into the influence of DNA shape and gene topology, Nadav Ahituv's research provides a comprehensive understanding of gene regulation at the molecular level, shedding light on the complexity of genetic interactions. The conversation delves into specific cases involving enhancers, gene sequencing, and 3D genomic structure, highlighting the impact of critical elements such as CTCF sites on gene expression. Discussions of haploid insufficiency and its implications for human health, using CRISPR technology to enhance gene expression, offer new possibilities for treating genetic diseases. Explorations of leptin-responsive regulatory elements in the hypothalamus and liver-associated transcription factors provide insights into metabolic regulation and gene expression networks in different tissues. The episode also explores the epigenomic landscape, the evolution of methods from bulk approaches to single-cell analyses, and the role of AI and machine learning in deciphering complex genetic patterns. The conversation transitions to a unique study of bat embryonic development, dietary differences, and their implications for understanding wing development and metabolism in different bat species.   References Ahituv, N., Zhu, Y., Visel, A., Holt, A., Afzal, V., Pennacchio, L. A., & Rubin, E. M. (2007). Deletion of ultraconserved elements yields viable mice. PLoS biology, 5(9), e234. https://doi.org/10.1371/journal.pbio.0050234 Matharu, N., Rattanasopha, S., Tamura, S., Maliskova, L., Wang, Y., Bernard, A., Hardin, A., Eckalbar, W. L., Vaisse, C., & Ahituv, N. (2019). CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. Science (New York, N.Y.), 363(6424), eaau0629. https://doi.org/10.1126/science.aau0629 Ushiki, A., Zhang, Y., Xiong, C., Zhao, J., Georgakopoulos-Soares, I., Kane, L., Jamieson, K., Bamshad, M. J., Nickerson, D. A., University of Washington Center for Mendelian Genomics, Shen, Y., Lettice, L. A., Silveira-Lucas, E. L., Petit, F., & Ahituv, N. (2021). Deletion of CTCF sites in the SHH locus alters enhancer-promoter interactions and leads to acheiropodia. Nature communications, 12(1), 2282. https://doi.org/10.1038/s41467-021-22470-z Georgakopoulos-Soares, I., Deng, C., Agarwal, V., Chan, C. S. Y., Zhao, J., Inoue, F., & Ahituv, N. (2023). Transcription factor binding site orientation and order are major drivers of gene regulatory activity. Nature communications, 14(1), 2333. https://doi.org/10.1038/s41467-023-37960-5 Gordon, W. E., Baek, S., Nguyen, H. P., Kuo, Y. M., Bradley, R., Fong, S. L., Kim, N., Galazyuk, A., Lee, I., Ingala, M. R., Simmons, N. B., Schountz, T., Cooper, L. N., Georgakopoulos-Soares, I., Hemberg, M., & Ahituv, N. (2024). Integrative single-cell characterization of a frugivorous and an insectivorous bat kidney and pancreas. Nature communications, 15(1), 12. https://doi.org/10.1038/s41467-023-44186-y   Related Episodes Ultraconserved Enhancers and Enhancer Redundancy (Diane Dickel) Enhancers and Chromatin Remodeling in Mammary Gland Development (Camila dos Santos) Enhancer-Promoter Interactions During Development (Yad Ghavi-Helm)   Contact Epigenetics Podcast on X Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Epigenetics Podcast on Threads Active Motif on X Active Motif on LinkedIn Email: podcast@activemotif.com

Dan is back with another episode of Redmen Weekly and clips this week contain talk about Darwin Nunez and his spontaneous deletion of anything Liverpool related from his Instagram and the title race, which no longer involves LFC.Support this show http://supporter.acast.com/redmentv. Hosted on Acast. See acast.com/privacy for more information.

This is a recap of the top 10 posts on Hacker News on May 3rd, 2024.This podcast was generated by wondercraft.ai(00:35): DNS traffic can leak outside the VPN tunnel on AndroidOriginal post: https://news.ycombinator.com/item?id=40247604&utm_source=wondercraft_ai(02:20): Woodworking as an escape from the absurdity of softwareOriginal post: https://news.ycombinator.com/item?id=40245601&utm_source=wondercraft_ai(04:00): Lithium-free sodium batteries exit the lab and enter US productionOriginal post: https://news.ycombinator.com/item?id=40248627&utm_source=wondercraft_ai(05:54): As private equity dominates wheelchair market, users wait months for repairsOriginal post: https://news.ycombinator.com/item?id=40250056&utm_source=wondercraft_ai(07:41): Evidence of price-fixing in the oil industry?Original post: https://news.ycombinator.com/item?id=40250226&utm_source=wondercraft_ai(09:32): How to Use JSON PathOriginal post: https://news.ycombinator.com/item?id=40245637&utm_source=wondercraft_ai(11:07): CSS Text Box TrimOriginal post: https://news.ycombinator.com/item?id=40247871&utm_source=wondercraft_ai(12:41): Deletion of user accountOriginal post: https://news.ycombinator.com/item?id=40246171&utm_source=wondercraft_ai(13:58): Lowercase – A simple way to take and share notesOriginal post: https://news.ycombinator.com/item?id=40248217&utm_source=wondercraft_ai(15:24): Microsoft ties executive pay to security after multiple failures and breachesOriginal post: https://news.ycombinator.com/item?id=40252619&utm_source=wondercraft_aiThis is a third-party project, independent from HN and YC. Text and audio generated using AI, by wondercraft.ai. Create your own studio quality podcast with text as the only input in seconds at app.wondercraft.ai. Issues or feedback? We'd love to hear from you: team@wondercraft.ai

Join us on the Fireside Chat as we chat with researcher and streamer Becca, AKA Bx. We will be talking about some things that might get us in trouble with YouTube, Facebook and Twitch, so the stream WILL move to Rumble and X after it starts.

Watch the Full Episode for FREE: Mike Benz - Weapons of Mass Deletion: How The US Government Funds The Digital Censorship Industrial Complex - London Real

Watch the Full Episode for FREE: Mike Benz - Weapons of Mass Deletion: How The US Government Funds The Digital Censorship Industrial Complex - London Real

This week we delve into the world of fetal cardiology when we review a recent large, multicenter study on the impact of prental diagnosis of 22.q11 deletion syndrome. How did the prenatally diagnosed patients differ from those diagnosed postnatally in regards to degree of heart disease and postnatal morbidity and mortality? What is the role of cell-free DNA testing in the screening for patients with this deletion syndrome? How do outcomes differ for this syndrome between the US and other countries and why might this be? These are amongst the many questions reviewed with the first author of this week's work, Dr. Lindsay Freud who is the director of fetal cardiology at Toronto Sick Kid's Hospital and also Associate Professor of Pediatrics at the University of Toronto. Also joining the podcast this week are the co-directors of this year's Mount Sinai Imaging Symposium entitled: Conversations in Care - The Single Ventricle. Dr. David Ezon, Dr. Jennifer Cohen, Dr. Kenan Stern and Mount Sinai Technical Director and Echo Lab Manager, Ms. Jen Lie Yau share their thoughts about the upcoming conference. This year's symposium will be taking place on May 4th, 2024 and the faculty are a who's who of important pediatric cardiac specialists from the worlds of imaging, interventional cardiology, sonography, surgery and more. For those interested, you can get more information about this wonderful conference at the following web address:https://mssm.cloud-cme.com/assets/MSSM/data/Single%20Ventricle%20Symposium24G.pdfToday's article link:DOI: 10.1016/j.ajog.2023.09.005

Best Selling Sci-Fi author and Visionary Futurist Steve Truitt talks with us about all things future. Take a step into the future with us. Do we get it right? you can find Steve at www.SteveTruitt.com and his sci-fi book "The Deletion" is the first of three in "The MindSet Chronicles"  We stream live video every sunday at 4 pm pacific only at www.SchrabHomeVideo.com visit RealLifeSciFi.show  We write on twitch Monday nights 8pm pacific at Twitch.TV/RealLifeSciFi Gaming with RoboticWilly on Thursday nights 7pm pacific Twitch.TV/RealLifeSciFi Support us and get more content at Patreon.com/reallifescifi we exist because of you. hit us up at WadeandWilly@gmail.com if you wanna try magic mind - go to www.magicmind.com/rlsf and if you want 50% off a subscription use the code RLSF20 Thank you for listening :)

Sneaky ChatGPT Data Leaks, A New Ground-Based Telescope, Companies Leaving Austin, More…

After losing her first son Alex at only 10 months of age to a rare genetic condition, Jill and her husband went on to have four more children. Jill's youngest daughter, Katie, was always small from birth. By the time she was 15 months old, it was obvious that Katie's growth was significantly delayed. By age 2, she had started on human growth hormone. At the time that we recorded this interview in 2021, Katie was 5 years old and had a suspected diagnosis of Russell Silver syndrome. Katie has since had genetic testing done and has been diagnosed with 22q Deletion syndrome. Jill shares how her experience with Alex meant that with each of her children, she felt like she was waiting for the other shoe to drop. She also discusses how her experience with Alex prepared her to be an excellent advocate for Katie. Links and Resources The Magic Foundation  To hear part one of Jill's story about her first child, Alex, listen to the last episode: Breaking Taboos & Leaving Room for Grief Check out other Patient Stories podcast episodes. Read other Patient Stories on the Grey Genetics Patient Stories Page. Interested in digging deeper into the professional issues raised in the podcast? Consider joining the Patient Stories Club! Do you want to support Patient Stories? You can make a donation online! Are you looking for genetic counseling? Patient Stories is sponsored by Grey Genetics, an independent telehealth genetic counseling and consulting company. Book an appointment with a genetic counselor specialized in your area of concern. All genetic counseling appointments take place over secure, HIPAA-compliant video-conferencing or by phone. Looking for a place to collect your family history and share with relatives? Check out the FamGenix app. Grey Genetics is no longer active on social media. To receive occasional email updates, sign up for our mailing list.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/patient-stories-with-grey-genetics/message

Amazon has entered the realm of companies offering their very own AI assistant that they've dubbed Amazon Q. How Gen Z is driving the adoption of Generative AI, in the U.K. at least. And starting December 1st, unused Gmail accounts may be permanently deleted if they have been inactive for at least two years. Amazon announced its own AI assistant called Amazon Q. Emily Dreibelbis of PCMag stops by to talk about the Amazon Q chatbot. Dan Moren of SixColors joins the show to reassure you that iOS 17's NameDrop feature is not dangerous at all. Jason Howell shares a study on how Gen Z in the U.K. is driving the general adoption of Generative AI. And Mikah Sargent warns us that if you have a Gmail account you haven't used in some time, it may be permanently deleted starting in the beginning of December. Hosts: Jason Howell and Mikah Sargent Guests: Emily Dreibelbis and Dan Moren Download or subscribe to this show at https://twit.tv/shows/tech-news-weekly. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: wix.com/studio?utm_campaign=pa_podcast_studio_10/ 23_TWiT%5Esponsors_cta GO.ACILEARNING.COM/TWIT discourse.org/twit

Amazon has entered the realm of companies offering their very own AI assistant that they've dubbed Amazon Q. How Gen Z is driving the adoption of Generative AI, in the U.K. at least. And starting December 1st, unused Gmail accounts may be permanently deleted if they have been inactive for at least two years. Amazon announced its own AI assistant called Amazon Q. Emily Dreibelbis of PCMag stops by to talk about the Amazon Q chatbot. Dan Moren of SixColors joins the show to reassure you that iOS 17's NameDrop feature is not dangerous at all. Jason Howell shares a study on how Gen Z in the U.K. is driving the general adoption of Generative AI. And Mikah Sargent warns us that if you have a Gmail account you haven't used in some time, it may be permanently deleted starting in the beginning of December. Hosts: Jason Howell and Mikah Sargent Guests: Emily Dreibelbis and Dan Moren Download or subscribe to this show at https://twit.tv/shows/tech-news-weekly. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: wix.com/studio?utm_campaign=pa_podcast_studio_10/ 23_TWiT%5Esponsors_cta GO.ACILEARNING.COM/TWIT discourse.org/twit

DiGeorge syndrome… what a complicated condition for such a little area of a single chromosome being affected. The condition's descriptive and preferred name is 22q11.2. This is called a microdeletion. Along with microduplications, microdeletions are collectively known as copy number variants. Copy number variants can lead to disease when the change in copy number of a dose-sensitive gene or genes disrupts the ability of the gene(s) to function and affects the amount of protein produced. Other examples of microdeletion syndromes include Prader- Willi, (which is a deletion on 15q), and Cri du chat syndrome which results from a microdeletion on 5p. In this episode, we will review the varied penetrance of DiGeorge syndrome and review its genetic basis. What are some suggestive features found on prenatal ultrasound? What are the associated abnormalities/phenotypes? And how is this condition managed after birth? And why is this also known as CATCH22. We will answer all of these questions, and more, in this episode.

Full Court Press: The Blockbuster Damian Lillard/Jrue Holiday Trades  An Interview With: HORSE's Official WNBA Correspondent Jordan Robinson  And Also: Emo Bassists, Karen, Ball Out Boy, Panic At The Free Throw, Jimmy Heat World, The Big H, Baby Ruth & Jeter Derek, Sheryl Scoops, The Sphere, Bill Laimbeer's Big Ass, Chomp, Mike Schubert Morning Voice   Sponsor: Tab for a Cause: Raise money for charity every time you open a new browser tab. Visit www.tabforacause.org/horse to start raising money today. Perfect for tab monsters like Adam! Find Us Online - website: horsehoops.com - patreon: patreon.com/horsehoops - twitter: twitter.com/horse_hoops - instagram: instagram.com/horsehoops - facebook: facebook.com/horsehoops   HORSE is hosted by Mike Schubert and Adam Mamawala. Edited by Kensei Tsurumaki. Theme song by Bettina Campomanes. Art by Allyson Wakeman. Website by Kelly Schubert.   About Us On HORSE, we don't analyze wins and losses. We talk beefs (beeves?), dig into Internet drama, and have fun. The NBA is now a 365-day league and it's never been more present in pop culture. From Kevin Durant's burner accounts to LeBron taking his talents anywhere to trusting the Process, the NBA is becoming a pop culture requirement. At the same time, sports can have gatekeepers that make it insular and frustrating for people who aren't die hard fans. We're here to prove that basketball is entertaining to follow for all fans, whether you're actively watching the games or not. Recently featured in The New York Times!

05:38 Social Deletion 18:47 Joe Namath 31:09 Mcafee in The Middle 43:18 Bonus Topic (Tyreek vs Micah) 50:18 Wiley's World / Funk Up 56:00 Wileyism Deleting your Social Media to avoid Trolls is not healthy! Zach Wilson is closer to being a good QB than people think, including Zach! Lou Holtz got in trouble talking to himself on Pat McAfee's show! Micah parsons and Tyreek Hill know it's all fun & games until it's not! Join the Wiley's World membership program at ProjectTransition.org to get access to exclusive perks, including hosting the show with Marcellus Wiley, free swag giveaways, and more! @marcelluswileydatdude Go to Brinx.TV for exclusive content! https://brinx.tv/channel/live #marcelluswiley #sports #sportsnews #nfl #football #nba #basketball #life #news #entertainment #tv #podcast #show #media #nfldraft #debate #draftpicks #draft #picks #undrafted #money #security #contract #signing #bonus #commitment #strategy #salary #talent #brinxtv #week1recap #nflweek2 #stephenA #terrellowens #colincowherdSupport the Show: https://linktr.ee/marcelluswileySee omnystudio.com/listener for privacy information.

Thanks to HelloFresh for sponsoring today's episode of Going In Raw! Go to http://www.hellofresh.com/gir16 and use code gir16 to get 16 free meals plus free shipping!! NEW MANIA MERCH DROP! http://www.friendoshop.com USE CODE MANIA TO GET 20% OFF! Sources https://wrestlingnews.co/wwe-news/wwe-likely-wont-be-holding-another-premium-live-event-in-puerto-rico-for-a-while https://www.wrestlinginc.com/1279813/world-heavyweight-title-tournament-matches-reportedly-revealed-for-tonights-wwe-raw/ http://www.fightfulselect.com Help support Going In Raw! Becoming a $5+ Patron at http://www.patreon.com/steveandlarson